UroToday

SNMMI 2026: Does Early 177Lu-PSMA-617 SPECT/CT Improve Prognostic Assessment Beyond Baseline PSMA PET in mCRPC?

The 2026 SNMMI annual meeting featured a genitourinary radiotherapeutics session and a presentation by Dr. Yalda Nikanpour ...
UroToday

SNMMI 2026: Impact of External Beam Radiotherapy Use and Timing on Clinical Outcomes in Patients Receiving 177Lu-PSMA-617 + Best Standard of Care: A Secon…

Dr. Pepin concluded her presentation discussing a secondary analysis of the VISION trial assessing the impact of external ...
UroToday

SNMMI 2026: Predicting Early PSA Response to 177Lu-PSMA Therapy using Baseline PET Imaging Biomarkers and Cycle 1 Dosimetry

Higher baseline PET SUVmean and cycle 1 whole body tumor volume absorbed dose are associated with a more favorable PSA response following early cycles of 177 Lu-PSMA, as well as after therapy ...
UroToday

Hydrogel Spacer Placement for Prostate Radiotherapy: A Urology Residency Training Experience - Zachary Klaassen

Zachary Klaassen discusses hydrogel spacer placement and resident education, drawing on approximately 250 Barrigel® procedures performed since FDA clearance in 2022. He describes ...
UroToday

SNMMI 2026: Survival in Veterans with Metastatic Hormone Sensitive Prostate Cancer Based on PSMA PET/CT Imaging

(UroToday.com) The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session and a presentation by Molly Wynveen discussing survival in Veterans with metastatic ...
UroToday

ASCO 2026: Final Analysis of the TiNivo-2 Phase 3 Trial: Long-Term Outcome of Tivozanib in Patients with mRCC

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...
UroToday

ASCO 2026: Discussant - Living Longer, Living Better: Can We Have It All?

Finally, current quality-of-life tools do not fully capture the patient experience. Emerging approaches incorporating patient ...
UroToday

SNMMI 2026: Safety and Efficacy of Rechallenge PSMA Radioligand Therapy in Post-Taxane mCRPC: An Early Single Center Experience

(UroToday.com) The 2026 SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Akshay Bedmutha discussing the safety and efficacy of rechallenge PSMA ...
UroToday

ASCO 2026: Phase 3 Study to Assess the Safety and Efficacy of 177Lu-Girentuximab in Advanced, Relapsed, or Recurrent ccRCC (LUTEON)

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. David Cade presented LUTEON, an ongoing phase III trial ...
UroToday

SNMMI 2026: Renal Function Stability in Patients Treated with 177Lu-PSMA-617: A Longitudinal Analysis of eGFR and Creatinine Trends During and After Therapy

The 2026 SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kiflom Gebreslassea discussing a longitudinal analysis of estimated glomerular filtration rate ...
UroToday

SNMMI 2026: Longitudinal Outcomes of PSMA PET/CT-Detected Bone Oligometastases: A Two-Center Study

The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session, including a presentation by Dr. Surekha Yadav discussing longitudinal outcomes of PSMA PET/CT-detected bone ...
UroToday

ASCO 2026: PEAK-1: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with ...

A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell RCC. Treatment options remain ...